Synaerion Therapeutics is a privately held biotechnology company dedicated to the discovery, development and commercialization of novel treatments for Amyotrophic Lateral Sclerosis.
Synaerion Therapeutics, Inc.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]
In May 2016, Synaerion entered into an exclusive technology sharing licensing agreement with RXi Pharmaceuticals, to utilize RXis technology to further develope RNA-based and small molecule therapeutic for Amyotrophic Lateral Sclerosis.
Synaerion has secured a $1.5 Mn grant from the Flemish Agency for Innovation and Entrepreneurship in Belgium, and is seeking additional $15 Mn in a series A financing to fund its research activities.